When Holt Sakai and his colleagues in David Liu’s lab at the Broad Institute watched their newly engineered pegRNAs survive ten times longer in liver cells than standard versions, they knew they were onto something transformative. This wasn’t just a lab win—it was a leap toward making prime editing, one of the most precise gene-editing tools ever developed, powerful enough to treat genetic diseases directly inside the human body. Until now, prime editing has largely been used outside the body, with cells removed, edited in the lab, and reinfused. But for diseases affecting organs like the liver, lungs, or muscles, the future lies in in vivo editing—fixing genes where they live.
Prime editing, first unveiled in 2019, holds the potential to correct up to 90% of known disease-causing genetic mutations. Unlike older gene-editing methods, it can swap out faulty DNA sequences with custom-designed ones, offering hope for conditions like sickle cell disease, cystic fibrosis, and certain forms of muscular dystrophy. But its clinical use has been held back by inefficiency—especially when delivered into the body. The components degrade too quickly, the editing doesn’t take in enough cells, and getting the machinery to the right tissues has been a persistent challenge.
Now, in three groundbreaking studies published in Nature Biotechnology and Nature Nanotechnology, Liu’s team has reengineered nearly every part of the system. They discovered new protective motifs for the prime editing guide RNA (pegRNA)—synthetic “shields” that prevent degradation. One motif, identified through screening thousands of natural and artificial sequences, boosted pegRNA abundance by over 10-fold in liver cells. At the same time, they enhanced the reverse transcriptase enzyme—the molecular “copy machine” that writes the corrected DNA sequence—making it more efficient and accurate.
Perhaps most crucially, the team optimized how these components are packaged and delivered using lipid nanoparticles (LNPs), the same delivery vehicles used in mRNA COVID-19 vaccines. By fine-tuning the ratio of pegRNA to editor protein within the LNPs, they achieved up to a 10-fold increase in editing efficiency in the liver of animal models. This means more cells receive the fix, with fewer doses—a critical advance for patient safety and practical treatment.
"Collectively, these three papers improve the overall efficiency and clinical relevance of prime editing, which we hope will make the technique more useful both for research purposes and for therapeutic clinical applications," said Liu, who is also a professor at Harvard and an HHMI investigator.
These advances don’t just refine a tool—they redefine what’s possible. With higher efficiency, longer-lasting components, and proven in vivo delivery, prime editing is moving from a revolutionary concept to a real therapeutic pathway. For millions living with genetic diseases, the next chapter of gene editing may not happen in a petri dish, but in the body itself—quietly, precisely, and potentially, permanently healing at the DNA level.